Quantcast

Latest Genmab Stories

2008-09-23 09:01:09

Genmab, an international biotechnology company, has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma patients in the Phase II study of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone. Patients in this open label study will be randomized into two dose groups of 28 patients each and will receive a total of six infusions of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)....

2008-09-22 09:00:58

COPENHAGEN, September 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). "We are happy to finish enrolment in this first study with ofatumumab in front line follicular NHL patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer...

1f5f20ccf84ea9e4eb75ca859981bbb21
2008-09-12 12:44:49

The head of biotech research GlaxoSmithKline Plc said a new generation of "slimline" antibody medicines may be successors to current blockbusters such as Avastin and Rituxan. Ian Tomlinson headed the next-generation antibody firm Domantis until Glaxo bought it for $405 million in 2006. Now a coming wave of ultra-small antibody products capable of working in ways impossible for conventional treatments is gaining attention. Tomlinson said he thinks the next generation approaches have tremendous...

2008-08-26 09:01:20

Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and follicular non-Hodgkin's lymphoma in 2008. The Phase III chronic lymphocytic leukemia (CLL) front line chlorambucil combination study is an open-label, parallel-arm study that will include 444 patients with previously untreated CLL. Patients in the study will be randomized to receive ofatumumab in combination with chlorambucil or chlorambucil alone. Patients receiving ofatumumab in combination...

2008-08-25 03:00:16

COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Genmab A/S (OMX: GEN) announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year. "Genmab and GSK have worked diligently to expand the ofatumumab development program to maximize the value of the antibody for patients and...

2008-08-21 12:01:28

COPENHAGEN, August 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the fifth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 232.7 million (approximately USD 48.5 million) was triggered by the achievement of positive results in the Phase III study of ofatumumab in refractory chronic lymphocytic leukemia (CLL). Genmab has received an approximate total of DKK 552...

2008-08-20 09:01:30

SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) therapies. Biogen/Elan's Tysabri has been under scrutiny due to two additional reported cases of PML, a rare and potentially fatal brain disease associated with use of the drug. MedPredict recently...

2008-07-31 12:01:05

COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need. At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary...

2008-07-23 09:01:21

ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (IMUC), a biotechnology company, announced today that it has signed a research agreement with Antitope Ltd. for the humanization of IMUC's monoclonal antibodies. IMUC is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential. "We have made solid progress in our antibody therapy program including signing research agreements with Antitope...

2008-07-10 09:00:14

Genmab has completed recruitment of 56 patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat chronic lymphocytic leukemia in previously untreated patients. Patients in this open label study will be randomized into two treatment groups of 28 patients each. Each patient will receive six monthly infusions of either 500 or 1000mg of ofatumumab in combination with fludarabine and cyclophosphamide (FC). Disease status will be measured every...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'